Liver Cancer

>

Latest News

Data from the TALENTACE trial support TACE plus atezolizumab/bevacizumab as an effective option in those with unresectable hepatocellular carcinoma.
PFS Improves With TACE-Based Regimen in Unresectable Liver Cancer

July 13th 2025

Data from the TALENTACE trial support TACE plus atezolizumab/bevacizumab as an effective option in those with unresectable hepatocellular carcinoma.

HAIC with oxaliplatin and raltitrexed produced a higher response rate vs other systemic therapy agents in patients with advanced hepatocellular carcinoma.
HAIC Regimen Yields Long-Term Survival in Unresectable HCC

July 8th 2025

SIR-Sphere Y-90 resin microspheres are the only approved radioembolization treatments in the US for both HCC and mCRC.
FDA Approves SIR-Sphere Y-90 in HCC

July 7th 2025

Survival benefits were observed across most post-hoc subgroups treated with anlotinib plus penpulimab, particularly among those with high-risk disease features.
Anlotinib/Penpulimab Enhances Survival vs Sorafenib in Unresectable HCC

May 30th 2025

Ten-fraction image-guided hypofractionated radiation therapy could be a feasible treatment option for portal vein tumor thrombosis in patients with HCC.
Hypofractionated RT Shows Portal Vein Tumor Thrombosis Control, OS in HCC

April 29th 2025